Asparaginase (ASNase) is a first-line enzyme-based anticancer drug for acute lymphatic leukemia and several aggressive subtypes of lymphoma, but is known for its notoriously poor pharmacokinetic profiles and strong immunogenicity, which necessitates polymer conjugation [54–56]. This evidence concerns the gene ASPG and lymphoma.